Distalmotion recently announced the first closing of its $150 million financing. This significant funding round reinforces the confidence of Distalmotion’s existing investors led by Revival Healthcare Capital.
Dexter – which is Distalmotion’s robotic platform – is now in day-to-day clinical use in Europe, successfully treating patients across a multitude of complex and high-volume procedures in general surgery, gynecology, and urology.
Dexter essentially makes robotic surgery more accessible, enabling wider adoption of robotic surgery. And Dexter is easily integrated into clinical practice. As it requires no additional infrastructure, it fits into every clinical setting, and it is mobile allowing for easy sharing across departments. This empowers institutions to scale robotics programs across surgical disciplines to offer more patients enhanced standards of care in both hospital and surgery center settings.
Here is a video of how the company works:
Funding round: The funding round will enable the way for US Food and Drug Administration (FDA) approval and to continue the acceleration of clinical experience in Europe.
KEY QUOTES:
“Dexter allows for ‘on-demand robotics’ and gives surgeons access to the benefits of both robotic and laparoscopic surgery, enabling best-in-class minimally invasive care for the patients. Surgeons can choose to operate entire procedures robotically, or they can leverage the ability to easily switch between the robotic and laparoscopic modalities to perform specialized tasks such as stapling with their preferred and trusted instruments. Surgeons are therefore empowered with choice and control.”
— Distalmotion CEO Michael Friedrich
“Dexter delivers what surgeons need most for when it matters most. It provides advanced dexterity for complex surgical steps such as suturing, dissection and working in confined spaces. Dexter’s open platform allows surgeons to choose the best-in-class tools and technology for each step of the procedure. It is compatible with all 3D laparoscopes which allows surgeons to leverage current and future imaging innovations.”
— Prof. Dieter Hahnloser, head of colorectal surgery at Lausanne University Hospital who performed the first general surgery procedure with Dexter in 2021
“This latest financing sets the stage for Distalmotion to accelerate our mission of expanding the adoption of Dexter to hospitals worldwide. We are very proud of our global leadership team’s accomplishment to bring Distalmotion’s technology to the market and to set the stage for the company’s entry into the US market.”
— Rick Anderson, Chairman of Revival and Chairman of Distalmotion
